# Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

> **NCT07340619** · PHASE2 · NOT_YET_RECRUITING · sponsor: **UNICANCER** · enrollment: 51 (estimated)

## Conditions studied

- Metastatic (Stage IV) Melanoma

## Interventions

- **DRUG:** prifetrastat monotherapy for 15 days then combination with fulvestrant
- **DRUG:** prifetrastat in combination with fulvestrant

## Key facts

- **NCT ID:** NCT07340619
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-18
- **Primary completion:** 2028-11-18
- **Final completion:** 2029-11-18
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07340619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07340619, "Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07340619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*